Site menu

Search by ticker code:
Generic filters


Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

CSL (ASX:CSL) share price in focus on potential multi-billion Swiss acquisition

The CSL Limited (ASX: CSL) share price is in focus on reports that it could be about to make a multi-billion acquisition for the Swiss business Vifor Pharma.

CSL to buy Vifor Pharma?

The Australian Financial Review is reporting that CSL is currently doing due diligence on the Swiss-based drag maker and developer Vifor Pharma.

Whilst it is headquartered in Switzerland, Vifor has operations all around the world.

In the 12 months to 30 June 2021, Vifor’s revenue was reportedly $2.66 billion from the sale of treatments for iron deficiency and chronic kidney disease.

According to Google Finance, Vifor Pharma has a market capitalisation of 6.75 billion Swiss Francs, which translates to $10.32 billion in Australian dollar terms. As you’ll notice, it’s a sizeable acquisition if it goes ahead.

How will the deal be funded?

According to reporting by the AFR’s Street Talk, CSL has tasked Bank of America’s investment banking unit to work on funding packages that could lead to it raising $4 billion from investors if the bid for Vifor is successful.

Reportedly, sources say that the negotiations were advanced as at Thursday afternoon, though it could still take “weeks” to reach a final agreement.

Would this be good for the CSL share price?

This deal would add around US$2 billion to CSL’s revenue, so it would diversify and add to CSL’s earnings.

The more that CSL can offer patients and clients, the better it can help the world (and make profit). CSL has a formidable research and development (R&D) department and is spending around 10% of its revenue each year on R&D.

R&D spending is really important because it unlocks the next earnings streams for new and improved healthcare products.

CSL has proven to be one of the most effective large ASX blue chips at growing globally and making returns. This deal could be another step in the long-term development of the business.

The CSL share price hasn’t done much over the last year and I’m not sure if it’s worth buying today, But, after getting a closer look at the details of a potential deal, I’d probably be happy about buying Vifor if I were a CSL shareholder.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content